On December 14–15, Moscow hosted Heart Failure 2018 Congress organized by the Heart Failure Society and supported by the Russian Society of Cardiology.
The Congress brought together 1585 doctors from Russia and other countries. The event focused on the topical issues of epidemiology, drug and non-drug therapy for heart failure, comorbidity and management of the end-stage heart failure. These topics were discussed during 27 plenary sessions and 4 lectures.
In his welcome address to the Congress, Prof. Evgeny Shlyakhto, Director General of the Almazov Centre and President of the Russian Society of Cardiology, announced plans to develop cardiology care in Russia.
The specialists from the Heart Failure Research Department of the Almazov Centre gave 17 presentations and presented 4 posters on the hot topics in the diagnosis and management of heart failure.
This year’s Congress focused on non-drug treatments for heart failure. Doctors Tatyana Lelyavina and Victoria Galenko presented posters on this topic at the dedicated symposium.
At the Transplantation Cardiology session, Petr Fedotov, MD, PhD, head of Research Laboratory for High-Tech Heart Failure Treatments and the specialists of Heart Failure Research Department Yulia Sazonova and Maria Simonenko presented their experience in managing patients before and after heart transplant and told about death risk factors in patients on the waiting list.
The final pros and cons session of the Congress aroused great interest among the participants.
The Congress addressed crucial issues of organizing cardiology care and establishing heart failure clinics in Russia, which gives hope for higher quality and standards in managing this condition.